ArticleBlood advances2024

Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia.

Daniel Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.